I have been seeking recovery from alcohol, heroin and pharmaceutical opioid use disorders since late 2013. The treatment system is fraught with barriers, especially so if you’re ...

South San Francisco, CA, January 30, 2025 – The California Institute for Regenerative Medicine (CIRM), one of the world’s largest institutions dedicated to regenerative medicine, has awarded nearly ...

Suzetrigine (Journavx) is the first new drug approved to treat acute pain in over 20 years and the first to be classified as ...

For the first time in two decades, the FDA has approved a new class of non-opioid pain medication, offering an alternative to addictive opioids for patients seeking pain relief. The drug ...

but even if suzetrigine replaces opioids as a first-line pain therapy option for only some procedures, that would reduce the healthcare system’s overall risk of inducing opioid use disorder in ...

Future of Healthcategory UK health system to offer cutting-edge gene therapy for sickle cell disease January 31, 2025 Future of Healthcategory US FDA approves Axsome Therapeutics' migraine drug ...

The FDA's sign-off on the medication comes as the agency says it is prioritizing supporting the development of non-opioid pain treatment. Suzetrigine is the first non-opioid analgesic – or ...

Aging Health. 2011;7(6):813-828. Common opioid side effects reported in the literature include urinary retention, pruritus, nausea and vomiting, CNS effects and respiratory effects. The incidence ...

The director predicted Journavx will get broad coverage, as payers are under serious pressure to cover non-opioid medications. He also doesn’t anticipate the drug will be subject to “step therapy,” a ...

The Indian government has decided to exempt customs duty on 36 life-saving drugs to enhance access to essential treatments ...

The product is indicated for the management of severe and persistent pain in opioid-tolerant patients ... direct customers by certified letter and is arranging for return and replacement of all ...